Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: A multicenter study

Ophthalmology

Volumn 121, Issue 10, 2014, Pages 1877-1884

  Takeuchi, Masaru ^a   Kezuka, Takeshi ^b   Sugita, Sunao ^c   Keino, Hiroshi ^d   Namba, Kenichi ^e   Kaburaki, Toshikatsu ^f   Maruyama, Kazuichi ^g   Nakai, Kei ^h   Hijioka, Kuniaki ⁱ   Shibuya, Etsuko ^j   Komae, Keiko ^f   Hori, Junko ^k   Ohguro, Nobuyuki ^l   Sonoda, Koh Hei ^m   Mizuki, Nobuhisa ^j   Okada, Annabelle A ^d   Ishibashi, Tatsuro ⁱ   Goto, Hiroshi ^b   Mochizuki, Manabu ⁿ  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c RIKEN Center for Biosystems Dynamics Research   (Japan)

^d KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ KYUSHU UNIVERSITY   (Japan)

^j YOKOHAMA CITY UNIVERSITY   (Japan)

^k NIPPON MEDICAL SCHOOL   (Japan)

^l Department of Orthopaedic Surgery   (Japan)

^m YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁿ TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BEHCET DISEASE; BEST CORRECTED VISUAL ACUITY; CLINICAL EVALUATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE INFLAMMATION; GASTROENTERITIS; HUMAN; INFUSION RELATED REACTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTICENTER STUDY; PNEUMONIA; QUESTIONNAIRE; RELAPSE; RETROSPECTIVE STUDY; TREATMENT DURATION; UVEITIS; VISUAL ACUITY; ANALYSIS OF VARIANCE; FEMALE; MALE; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; FEMALE; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; RETROSPECTIVE STUDIES; UVEITIS; VISUAL ACUITY; YOUNG ADULT;

EID: 84908129409     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.04.042     Document Type: Article

References (43)

1. T. Chajek, and M. Fainaru Behcet's disease. Report of 41 cases and a review of the literature Medicine (Baltimore) 54 1975 179 196
2. R.C. Wong, C.N. Ellis, and L.A. Diaz Behcet's disease Int J Dermatol 23 1984 25 32
3. T. Sakane, M. Takeno, N. Suzuki, and G. Inaba Behcet's disease N Engl J Med 341 1999 1284 1291
4. S. Kotake, K. Namba, and K. Higashi The change of clinical manifestations of patients with Behcet's disease in Japan Adv Exp Med Biol 528 2003 83 84
5. A. Yoshida, H. Kawashima, and Y. Motoyama Comparison of patients with Behcet's disease in the 1980s and 1990s Ophthalmology 111 2004 810 815
6. J.G. Mamo The rate of visual loss in Behcet's disease Arch Ophthalmol 84 1970 451 452
7. S. Mishima, K. Masuda, and Y. Izawa The eighth Frederick H. Verhoeff Lecture. Presented by Saiichi Mishima, MD. Behcet's disease in Japan: ophthalmologic aspects Trans Am Ophthalmol Soc 77 1979 225 279
8. M. Muhaya, S. Lightman, and E. Ikeda Behcet's disease in Japan and in Great Britain: a comparative study Ocul Immunol Inflamm 8 2000 141 148
9. V. Hamuryudan, Y. Ozyazgan, and N. Hizli Azathioprine in Behcet's syndrome: effects on long-term prognosis Arthritis Rheum 40 1997 769 774
10. I. Tugal-Tutkun, S. Onal, and R. Altan-Yaycioglu Uveitis in Behcet disease: an analysis of 880 patients Am J Ophthalmol 138 2004 373 380
11. V.G. Kaklamani, and P.G. Kaklamanis Treatment of Behcet's disease-an update Semin Arthritis Rheum 30 2001 299 312
12. A.A. Okada Drug therapy in Behcet's disease Ocul Immunol Inflamm 8 2000 85 91
13. P.P. Sfikakis, P.G. Theodossiadis, and C.G. Katsiari Effect of infliximab on sight-threatening panuveitis in Behcet's disease [letter] Lancet 358 2001 295 296
14. S. Ohno, S. Nakamura, and S. Hori Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis J Rheumatol 31 2004 1362 1368
15. P.H. Goossens, R.J. Verburg, and F.C. Breedveld Remission of Behcet's syndrome with tumour necrosis factor alpha blocking therapy Ann Rheum Dis 60 2001 637
16. S. Munoz-Fernandez, V. Hidalgo, and J. Fernandez-Melon Effect of infliximab on threatening panuveitis in Behcet's disease [letter] Lancet 358 2001 1644
17. Y. Mizushima Revised diagnostic criteria for Behcet's disease in 1987 [in Japanese] Ryumachi 28 1988 66 70
18. T. Ito, K.H. Sonoda, and K. Hijioka Acquired resistance to infliximab against uveitis due to Behcet's disease after one year of administration [letter] Jpn J Ophthalmol 54 2010 502 504
19. Y. Yamada, S. Sugita, and H. Tanaka Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease Br J Ophthalmol 94 2010 284 288
20. H. Tanaka, S. Sugita, and Y. Yamada Effects and safety of infliximab administration in refractory uveoretinitis with Behcet's disease [in Japanese] Nihon Ganka Gakkai Zasshi 114 2010 87 95
21. Y. Yamada, S. Sugita, and H. Tanaka Timing of recurrent uveitis in patients with Behcet's disease receiving infliximab treatment Br J Ophthalmol 95 2011 205 208
22. H. Keino, A.A. Okada, T. Watanabe, and W. Taki Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy Br J Ophthalmol 95 2011 1245 1250
23. A.A. Okada, H. Goto, S. Ohno, M. Mochizuki Ocular Behçet's Disease Research Group of Japan Multicenter study of infliximab for refractory uveoretinitis in Behcet disease Arch Ophthalmol 130 2012 592 598
24. M. Takeuchi, Y. Asukata, and T. Kawagoe Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with Behcet's disease Ocul Immunol Inflamm 20 2012 193 197
25. T. Nishida, E. Shibuya, and Y. Asukata Clinical course before and after cataract and glaucoma surgery under systemic infliximab therapy in patients with Behcet's disease Case Rep Ophthalmol [serial online] 2 2011 189 192 Available at: http://www.karger.com/Article/Abstract/329190 Accessed April 16, 2014
26. M. Takamoto, T. Kaburaki, and J. Numaga Long-term infliximab treatment for Behcet's disease Jpn J Ophthalmol 51 2007 239 240
27. A. Yoshida, T. Kaburaki, and K. Okinaga Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy Jpn J Ophthalmol 56 2012 536 543
28. D. Iwata, K. Namba, and K. Mizuuchi Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behcet's disease with infliximab Graefes Arch Clin Exp Ophthalmol 250 2012 1081 1087
29. K. Namba Infliximab treatment for Behcet's disease-beginning of the biological drug era [in Japanese] Nihon Ganka Gakkai Zasshi 114 2010 85 86
30. S. Sugita, Y. Yamada, and M. Mochizuki Relationship between serum infliximab levels and acute uveitis attacks in patients with Behcet disease Br J Ophthalmol 95 2011 549 552
31. T. Hayashi, and N. Mizuki Ocular manifestations in Behçet's disease Japan Med Assoc J 49 7-8 2006 260 268
32. G. Simonini, M.E. Zannin, and R. Caputo Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis Rheumatology (Oxford) 47 2008 1510 1514
33. M. De Bandt, J. Sibilia, X. Le Loet Club Rhumatismes et Inflammation Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey Arthritis Res Ther 7 2005 R545 R551
34. M. Ramos-Casals, P. Brito-Zeron, and S. Munoz Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases Medicine (Baltimore) 86 2007 242 251
35. J. Lin, D. Ziring, and S. Desai TNFalpha blockade in human diseases: an overview of efficacy and safety Clin Immunol 126 2008 13 30
36. E.S. Chung, M. Packer, K.H. Lo ATTACH Investigators Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial Circulation 107 2003 3133 3140
37. S. Domm, J. Cinatl, and U. Mrowietz The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature Br J Dermatol 159 2008 1217 1228
38. E. Salgado, and J.J. Gomez-Reino The risk of tuberculosis in patients treated with TNF antagonists Expert Rev Clin Immunol 7 2011 329 340
39. E.C. Keystone Does anti-tumor necrosis factor-alpha therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis? a review of longterm data J Rheumatol 38 2011 1552 1562
40. A.M. Abu El-Asrar, E.B. Abboud, H. Aldibhi, and A. Al-Arfaj Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behcet's disease Int Ophthalmol 26 2005 83 92
41. M. Accorinti, M.P. Pirraglia, and M.P. Paroli Infliximab treatment for ocular and extraocular manifestations of Behcet's disease Jpn J Ophthalmol 51 2007 191 196
42. L. Niccoli, C. Nannini, and M. Benucci Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study Rheumatology (Oxford) 46 2007 1161 1164
43. M.J. Capella, and C.S. Foster Long-term efficacy and safety of infliximab in the treatment of Behcet's disease Ocul Immunol Inflamm 20 2012 198 202